# Palatin Technologies Inc: financial statements, quarterly

PTN · Nasdaq · CIK 911216 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Jun 30

Pages: [Overview](/companies/ptn.md) · [Financials](/companies/ptn/financials.md) · [Filings](/companies/ptn/filings.md) · [Insiders](/companies/ptn/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/ptn/financials.md?period=annual).

## Income statement

| Line item | Unit | Q1 FY2024 (2023-09-30) | Q2 FY2024 (2023-12-31) | Q3 FY2024 (2024-03-31) | Q4 FY2024 (2024-06-30) | Q1 FY2025 (2024-09-30) | Q2 FY2025 (2024-12-31) | Q3 FY2025 (2025-03-31) | Q4 FY2025 (2025-06-30) | Q1 FY2026 (2025-09-30) | Q2 FY2026 (2025-12-31) | Q3 FY2026 (2026-03-31) | Q4 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [2.1](/filings/0001654954-23-014251.md) | [2.0](/filings/0001654954-24-001789.md) | [0.0](/filings/0001654954-25-005610.md) | [0.4 d](/filings/0001654954-25-011030.md) | [0.0](/filings/0001654954-25-013091.md) | not reported | [0.0](/filings/0001654954-25-005610.md) | [0.0 d](/filings/0001654954-25-011030.md) | [8.8](/filings/0001493152-26-022778.md) | [0.1](/filings/0001493152-26-006969.md) | [3.9](/filings/0001493152-26-022778.md) | [0.3 d](/filings/0001493152-26-044572.md) |
| Cost of revenue | $m | [0.0](/filings/0001654954-23-014251.md) | [0.1](/filings/0001654954-24-001789.md) | [0.0](/filings/0001654954-24-006292.md) | [0.0 d](/filings/0001654954-24-012498.md) | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Research and development | $m | [5.0](/filings/0001654954-24-014335.md) | [5.6](/filings/0001654954-25-001431.md) | [7.2](/filings/0001654954-25-005610.md) | [4.7 d](/filings/0001654954-25-011030.md) | [5.7](/filings/0001654954-25-013091.md) | [3.4](/filings/0001493152-26-006969.md) | [3.8](/filings/0001493152-26-022778.md) | [2.0 d](/filings/0001493152-26-044572.md) | [2.5](/filings/0001654954-25-013091.md) | [4.3](/filings/0001493152-26-006969.md) | [3.5](/filings/0001493152-26-022778.md) | [2.0 d](/filings/0001493152-26-044572.md) |
| Selling, general and administrative | $m | [3.2](/filings/0001654954-24-014335.md) | [3.0](/filings/0001654954-25-001431.md) | [2.0](/filings/0001654954-25-005610.md) | [4.0 d](/filings/0001654954-25-011030.md) | [2.0](/filings/0001654954-25-013091.md) | [1.7](/filings/0001654954-25-001431.md) | [1.5](/filings/0001654954-25-005610.md) | [2.6 d](/filings/0001654954-25-011030.md) | [1.7](/filings/0001654954-25-013091.md) | not reported | not reported | not reported |
| Operating income | $m | [(6.1)](/filings/0001654954-24-014335.md) | [1.2](/filings/0001654954-25-001431.md) | [(9.2)](/filings/0001654954-25-005610.md) | [(8.3) d](/filings/0001654954-25-011030.md) | [(7.8)](/filings/0001654954-25-013091.md) | [(2.6)](/filings/0001493152-26-006969.md) | [(4.8)](/filings/0001493152-26-022778.md) | [(2.3) d](/filings/0001493152-26-044572.md) | [4.7](/filings/0001654954-25-013091.md) | [(7.3)](/filings/0001493152-26-006969.md) | [(1.6)](/filings/0001493152-26-022778.md) | [(4.4) d](/filings/0001493152-26-044572.md) |
| Interest expense | $m | [0.0](/filings/0001654954-24-014335.md) | [0.0](/filings/0001654954-25-001431.md) | [0.0](/filings/0001654954-25-005610.md) | [0.0 d](/filings/0001654954-25-011030.md) | [0.0](/filings/0001654954-25-013091.md) | [0.0](/filings/0001654954-25-001431.md) | [0.0](/filings/0001654954-25-005610.md) | [0.0 d](/filings/0001654954-25-011030.md) | [0.0](/filings/0001654954-25-013091.md) | [0.0](/filings/0001493152-26-006969.md) | [0.0](/filings/0001493152-26-022778.md) | [0.0 d](/filings/0001493152-26-044572.md) |
| Income tax | $m | not reported | [0.0](/filings/0001654954-24-001789.md) | [0.0](/filings/0001654954-24-006292.md) | [(29.7) d](/filings/0001493152-26-044572.md) | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Net income | $m | [(5.2)](/filings/0001654954-24-014335.md) | [(7.8)](/filings/0001654954-25-001431.md) | [(8.4)](/filings/0001654954-25-005610.md) | [(8.3) d](/filings/0001654954-25-011030.md) | [(7.8)](/filings/0001654954-25-013091.md) | [(2.4)](/filings/0001493152-26-006969.md) | [(4.8)](/filings/0001493152-26-022778.md) | [(2.2) d](/filings/0001493152-26-044572.md) | [4.7](/filings/0001654954-25-013091.md) | [(7.3)](/filings/0001493152-26-006969.md) | [(1.4)](/filings/0001493152-26-022778.md) | [(4.4) d](/filings/0001493152-26-044572.md) |
| Diluted EPS | $ per share | not reported | not reported | [(0.53)](/filings/0001654954-25-005610.md) | not reported | [(19.71)](/filings/0001654954-25-013091.md) | [(5.92)](/filings/0001493152-26-006969.md) | [(9.13)](/filings/0001493152-26-022778.md) | not reported | [4.26](/filings/0001654954-25-013091.md) | [(2.86)](/filings/0001493152-26-006969.md) | [(0.37)](/filings/0001493152-26-022778.md) | not reported |
| Basic EPS | $ per share | [(0.43)](/filings/0001654954-24-014335.md) | [(0.56)](/filings/0001654954-25-001431.md) | not reported | not reported | [(19.71)](/filings/0001654954-25-013091.md) | [(5.92)](/filings/0001493152-26-006969.md) | [(9.13)](/filings/0001493152-26-022778.md) | not reported | [4.81](/filings/0001654954-25-013091.md) | [(2.86)](/filings/0001493152-26-006969.md) | [(0.37)](/filings/0001493152-26-022778.md) | not reported |

- Revenue: us-gaap:Revenues, us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
- Cost of revenue: us-gaap:CostOfRevenue
- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Selling, general and administrative: us-gaap:SellingGeneralAndAdministrativeExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Interest expense: us-gaap:InterestExpense, us-gaap:InterestExpenseNonoperating
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q2 FY2024 (2023-12-31) | period not labelled (2024-01-31) | Q3 FY2024 (2024-03-31) | FY2024 (2024-06-30) | Q1 FY2025 (2024-09-30) | Q2 FY2025 (2024-12-31) | Q3 FY2025 (2025-03-31) | FY2025 (2025-06-30) | Q1 FY2026 (2025-09-30) | Q2 FY2026 (2025-12-31) | Q3 FY2026 (2026-03-31) | FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [9.5](/filings/0001654954-24-001789.md) | [9.2](/filings/0001654954-24-001789.md) | [21.5](/filings/0001654954-24-006292.md) | [9.5](/filings/0001654954-24-012498.md) | [2.4](/filings/0001654954-24-014335.md) | not reported | [2.5](/filings/0001654954-25-005610.md) | [2.6](/filings/0001493152-26-044572.md) | [1.3](/filings/0001654954-25-013091.md) | [14.5](/filings/0001493152-26-006969.md) | [10.2](/filings/0001493152-26-022778.md) | [7.5](/filings/0001493152-26-044572.md) |
| Current assets | $m | [12.2](/filings/0001654954-24-001789.md) | not reported | [10.3](/filings/0001654954-24-006292.md) | [9.8](/filings/0001654954-25-011030.md) | [2.6](/filings/0001654954-24-014335.md) | [3.7](/filings/0001654954-25-001431.md) | [3.2](/filings/0001654954-25-005610.md) | [2.9](/filings/0001493152-26-044572.md) | [8.4](/filings/0001654954-25-013091.md) | [17.5](/filings/0001493152-26-006969.md) | [12.8](/filings/0001493152-26-022778.md) | [8.2](/filings/0001493152-26-044572.md) |
| Total assets | $m | [13.6](/filings/0001654954-24-001789.md) | not reported | [11.4](/filings/0001654954-24-006292.md) | [10.7](/filings/0001654954-25-011030.md) | [3.4](/filings/0001654954-24-014335.md) | [4.3](/filings/0001654954-25-001431.md) | [3.7](/filings/0001654954-25-005610.md) | [3.3](/filings/0001493152-26-044572.md) | [8.6](/filings/0001654954-25-013091.md) | [17.9](/filings/0001493152-26-006969.md) | [13.2](/filings/0001493152-26-022778.md) | [8.5](/filings/0001493152-26-044572.md) |
| Current liabilities | $m | [11.2](/filings/0001654954-24-001789.md) | not reported | [8.5](/filings/0001654954-24-006292.md) | [9.7](/filings/0001654954-25-011030.md) | [9.9](/filings/0001654954-24-014335.md) | [9.6](/filings/0001654954-25-001431.md) | [10.0](/filings/0001654954-25-005610.md) | [8.0](/filings/0001493152-26-044572.md) | [8.2](/filings/0001654954-25-013091.md) | [6.3](/filings/0001493152-26-006969.md) | [2.5](/filings/0001493152-26-022778.md) | [1.8](/filings/0001493152-26-044572.md) |
| Total liabilities | $m | [24.5](/filings/0001654954-24-001789.md) | not reported | [9.8](/filings/0001654954-24-006292.md) | [10.9](/filings/0001654954-25-011030.md) | [11.1](/filings/0001654954-24-014335.md) | [10.7](/filings/0001654954-25-001431.md) | [10.1](/filings/0001654954-25-005610.md) | [8.0](/filings/0001493152-26-044572.md) | [8.2](/filings/0001654954-25-013091.md) | [6.5](/filings/0001493152-26-006969.md) | [2.6](/filings/0001493152-26-022778.md) | [1.8](/filings/0001493152-26-044572.md) |
| Long-term debt | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Shareholders' equity | $m | [(11.4)](/filings/0001654954-25-005610.md) | not reported | [1.6](/filings/0001654954-25-005610.md) | [(0.1)](/filings/0001493152-26-044572.md) | [(7.7)](/filings/0001493152-26-006969.md) | [(6.4)](/filings/0001493152-26-022778.md) | [(6.4)](/filings/0001493152-26-022778.md) | [(4.8)](/filings/0001493152-26-044572.md) | [0.4](/filings/0001493152-26-006969.md) | [11.5](/filings/0001493152-26-022778.md) | [10.6](/filings/0001493152-26-022778.md) | [6.7](/filings/0001493152-26-044572.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Long-term debt: not reported
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q1 FY2024 (2023-09-30) | Q2 FY2024 (2023-12-31) | Q3 FY2024 (2024-03-31) | Q4 FY2024 (2024-06-30) | Q1 FY2025 (2024-09-30) | Q2 FY2025 (2024-12-31) | Q3 FY2025 (2025-03-31) | Q4 FY2025 (2025-06-30) | Q1 FY2026 (2025-09-30) | Q2 FY2026 (2025-12-31) | Q3 FY2026 (2026-03-31) | Q4 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $m | [(5.9)](/filings/0001654954-24-014335.md) | [(10.5) d](/filings/0001654954-25-001431.md) | [(8.6) d](/filings/0001654954-25-005610.md) | [(6.5) d](/filings/0001654954-25-011030.md) | [(7.0)](/filings/0001654954-25-013091.md) | [(4.8) d](/filings/0001493152-26-006969.md) | [(5.4) d](/filings/0001493152-26-022778.md) | [(4.1) d](/filings/0001493152-26-044572.md) | [(1.6)](/filings/0001654954-25-013091.md) | [(4.8) d](/filings/0001493152-26-006969.md) | [(4.4) d](/filings/0001493152-26-022778.md) | [(2.7) d](/filings/0001493152-26-044572.md) |
| Capital expenditure | $m | [0.0](/filings/0001654954-23-014251.md) | [0.0 d](/filings/0001654954-25-001431.md) | [0.0 d](/filings/0001654954-25-005610.md) | [0.0 d](/filings/0001654954-25-011030.md) | not reported | not reported | [0.0 d](/filings/0001654954-25-005610.md) | [0.0 d](/filings/0001654954-25-011030.md) | not reported | not reported | [0.0 d](/filings/0001493152-26-022778.md) | [0.0 d](/filings/0001493152-26-044572.md) |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment

## Shares

| Line item | Unit | Q4 FY2019 (2019-06-30) | Q1 FY2020 (2019-09-30) | Q2 FY2020 (2019-12-31) | Q3 FY2020 (2020-03-31) | Q4 FY2020 (2020-06-30) | Q3 FY2024 (2024-03-31) | Q1 FY2025 (2024-09-30) | Q2 FY2025 (2024-12-31) | Q3 FY2025 (2025-03-31) | Q1 FY2026 (2025-09-30) | Q2 FY2026 (2025-12-31) | Q3 FY2026 (2026-03-31) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [229](/filings/0001654954-20-010471.md) | [233](/filings/0001654954-20-010471.md) | [235](/filings/0001654954-20-010471.md) | [235](/filings/0001654954-20-010471.md) | [235](/filings/0001654954-20-010471.md) | [15.8](/filings/0001654954-25-005610.md) | [0.4](/filings/0001654954-25-013091.md) | [0.4](/filings/0001493152-26-006969.md) | [0.5](/filings/0001493152-26-022778.md) | [1.1](/filings/0001654954-25-013091.md) | [2.5](/filings/0001493152-26-006969.md) | [3.9](/filings/0001493152-26-022778.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 1,780,939 at 2026-09-25, from the cover of the [10-K filed 2026-09-28](/filings/0001493152-26-044572.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:28 ET. No prices; not investment advice.